Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss drug maker Novartis has commenced supply of Fluvirin influenza virus vaccine to the US for early vaccination of priority individuals, including seniors, pregnant women and those with chronic illnesses.
Subscribe to our email newsletter
The company intends to send around 30 million doses of its US Food and Drug Administration (FDA) approved seasonal influenza vaccine for the US market.
Novartis‘ Fluvirin influenza virus vaccine is indicated for active immunization of persons 4 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
North America Vaccines head and US Vaccines president Vas Narasimhan said Novartis is again delivering Fluvirin to the US well ahead of schedule and with sufficient supply to meet customer demand.
"The early arrival of the influenza vaccine will allow public health professionals to administer vaccinations weeks ahead of their normal schedule, meeting an important public health need to help protect as many individuals as possible," Narasimhan said.